These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 11679499)
21. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Rizk B; Aboulghar M; Smitz J; Ron-El R Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101 [TBL] [Abstract][Full Text] [Related]
22. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507 [TBL] [Abstract][Full Text] [Related]
28. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model. Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730 [TBL] [Abstract][Full Text] [Related]
29. Follicle-stimulating hormone plays a role in the induction of ovarian follicular cysts in hypophysectomized rats. Bogovich K Biol Reprod; 1992 Aug; 47(2):149-61. PubMed ID: 1327203 [TBL] [Abstract][Full Text] [Related]
30. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH. van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671 [TBL] [Abstract][Full Text] [Related]
31. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114 [TBL] [Abstract][Full Text] [Related]
32. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study. Kosmas IP; Kitsou C; Lazaros L; Markoula S; Peschos D; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos A; Galani V; Georgiou I Gynecol Endocrinol; 2015; 31(9):702-7. PubMed ID: 26172931 [TBL] [Abstract][Full Text] [Related]
33. Circulatory dysfunction in asymptomatic in vitro fertilization patients. Relationship with hyperestrogenemia and activity of endogenous vasodilators. Manau D; Balasch J; Arroyo V; Jiménez W; Fábregues F; Casamitjana R; Creus M; Vanrell JA J Clin Endocrinol Metab; 1998 May; 83(5):1489-93. PubMed ID: 9589644 [TBL] [Abstract][Full Text] [Related]
34. Ovulation induction with low doses of "pure" follicle stimulating hormone using a fixed protocol in patients with polycystic ovarian disease. Bregieiro LO; de Moura MD; Ferriani RA; Bailão LA; de Sá MF Int J Fertil Menopausal Stud; 1993; 38(3):152-9. PubMed ID: 8348163 [TBL] [Abstract][Full Text] [Related]
35. The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary. Yarali H; Fleige-Zahradka BG; Yuen BH; McComb PF Fertil Steril; 1993 Mar; 59(3):657-61. PubMed ID: 8458471 [TBL] [Abstract][Full Text] [Related]
36. Angiotensin converting enzyme inhibition of the gonadotropin-stimulated rabbit: effect on estradiol production. Morris RS; Wong IL; Paulson RJ J Assist Reprod Genet; 1995 May; 12(5):326-9. PubMed ID: 8520197 [TBL] [Abstract][Full Text] [Related]
37. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Papaleo E; Doldi N; De Santis L; Marelli G; Marsiglio E; Rofena S; Ferrari A Hum Reprod; 2001 Nov; 16(11):2263-6. PubMed ID: 11679501 [TBL] [Abstract][Full Text] [Related]
38. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization. de Jong D; Macklon NS; Mannaerts BM; Coelingh Bennink HJ; Fauser BC Hum Reprod; 1998 Mar; 13(3):573-5. PubMed ID: 9572414 [TBL] [Abstract][Full Text] [Related]
39. The relation of serum and follicular fluid leptin and ovarian steroid levels in response to induction of ovulation in in vitro fertilization cycles. Gürbüz B; Yalti S; Ficicioglu C; Taşdemir S Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):214-8. PubMed ID: 15653206 [TBL] [Abstract][Full Text] [Related]
40. Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome. Di Carlo C; Bruno P; Cirillo D; Morgera R; Pellicano M; Nappi C Hum Reprod; 1997 Oct; 12(10):2115-7. PubMed ID: 9402264 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]